SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Dagenais Gilles)
 

Sökning: WFRF:(Dagenais Gilles) > (2020-2021) > Lowering cholestero...

Lowering cholesterol, blood pressure, or both to prevent cardiovascular events : results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Bosch, Jackie (författare)
Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada.;McMaster Univ, Sch Rehabil Sci, IAHS, Room 403,1400 Main St West, Hamilton, ON L8S 1C7, Canada.
Lonn, Eva M. (författare)
Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada.;McMaster Univ, Dept Med, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada.
Jung, Hyejung (författare)
Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada.
visa fler...
Zhu, Jun (författare)
Chinese Acad Med Sci & Peking Union Med Coll, Fu Wai Hosp, 9 Dongdan 3rd Alley, Beijing, Peoples R China.
Liu, Lisheng (författare)
Chinese Acad Med Sci & Peking Union Med Coll, Fu Wai Hosp, 9 Dongdan 3rd Alley, Beijing, Peoples R China.
Lopez-Jaramillo, Patricio (författare)
Univ Santander, Fac Salud, Inst Masira, Calle 70 55-210, Bucaramanga, Colombia.
Pais, Prem (författare)
St Johns Res Inst, 100 Feet Rd, Bangalore 560034, Karnataka, India.
Xavier, Denis (författare)
St Johns Res Inst, 100 Feet Rd, Bangalore 560034, Karnataka, India.;St Johns Med Coll, Sarjarpur Rd, Bangalore 560034, Karnataka, India.
Diaz, Rafael (författare)
Inst Cardiovasc Rosario, DSR, Bv Orono 440,S2000, RA-440 Rosario, Santa Fe, Argentina.
Dagenais, Gilles (författare)
Univ Laval, Inst Univ Cardiol & Pneumol Quebec, 2725 Ch Ste Foy, Ste Foy, PQ G1V 4G5, Canada.
Dans, Antonio (författare)
Univ Philippines, Coll Med, Pedro Gil St,Taft Ave, Manila 1000, Metro Manila, Philippines.
Avezum, Alvaro (författare)
Dante Pazzanese Inst Cardiol, Av Dr Dante Pazzanese 500, BR-04012909 Sao Paulo, SP, Brazil.;Univ Sao Paulo, Av Dr Dante Pazzanese 500, BR-04012909 Sao Paulo, SP, Brazil.
Piegas, Leopoldo S. (författare)
HCor Hosp Coracao, Eliseu Guilherme 147, BR-04004030 Sao Paulo, SP, Brazil.
Parkhomenko, Alexander (författare)
Inst Cardiol, Narodnoho Opolchennya St 5, UA-03680 Kiev, Ukraine.
Keltai, Kati (författare)
Semmelweis Univ, Hungarian Inst Cardiol, Budapest, Hungary.
Keltai, Matyas (författare)
Semmelweis Univ, Hungarian Inst Cardiol, Budapest, Hungary.
Sliwa, Karen (författare)
Univ Cape Town, Hatter Inst Cardiovasc Res, Dept Med, Soweto Cardiovasc Res Grp, 4th 5th & 6th Floor, Cape Town, South Africa.
Held, Claes, 1956- (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Peters, Ronald J. G. (författare)
Acad Med Ctr, Dept Cardiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
Lewis, Basil S. (författare)
Technion Israel Inst Technol, Lady Davis Carmel Med Ctr, Ruth & Bruce Rappaport Sch Med, Efron St 1, Haifa, Israel.
Jansky, Petr (författare)
Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.
Yusoff, Khalid (författare)
Univ Teknol Majlis Amansh Rakyat, Jalan Ilmu 1-1, Shah Alam 40450, Selangor, Malaysia.;Univ Coll Sedaya Int Univ, UCSI Hts,1 Jalan Puncak Menara Gading, Kuala Lumpur 56000, Malaysia.
Khunti, Kamlesh (författare)
Leicester Diabet Ctr, Gwendolen Rd, Leicester LE5 4PW, Leics, England.
Toff, William D. (författare)
Univ Leicester, Dept Cardiovasc Sci, Univ Rd, Leicester LE1 7RH, Leics, England.;Glenfield Hosp, Leicester Biomed Res Ctr, UK & Natl Inst Hlth Res, Groby Rd, Leicester LE3 9QP, Leics, England.
Reid, Christopher M. (författare)
Monash Univ, Sch Publ Hlth & Prevent Med, 553 St Kilda Rd, Melbourne, Vic 553, Australia.;Curtin Univ, Sch Publ Hlth, Kent St, Bentley Perth, WA 6102, Australia.
Varigos, John (författare)
Monash Univ, Sch Publ Hlth & Prevent Med, 553 St Kilda Rd, Melbourne, Vic 553, Australia.
Joseph, Philip (författare)
Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada.;McMaster Univ, Sch Rehabil Sci, IAHS, Room 403,1400 Main St West, Hamilton, ON L8S 1C7, Canada.
Leiter, Lawrence A. (författare)
Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, 209 St, Toronto, ON M5B 1T8, Canada.;Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, 209 Victoria St, Toronto, ON M5B 1T8, Canada.;Univ Toronto, Keenan Res Ctr Biomed Sci, St Michaels Hosp, 209 Victoria St, Toronto, ON M5B 1T8, Canada.
Yusuf, Salim (författare)
Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada.;McMaster Univ, Sch Rehabil Sci, IAHS, Room 403,1400 Main St West, Hamilton, ON L8S 1C7, Canada.
visa färre...
Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada;McMaster Univ, Sch Rehabil Sci, IAHS, Room 403,1400 Main St West, Hamilton, ON L8S 1C7, Canada. Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada.;McMaster Univ, Dept Med, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada. (creator_code:org_t)
2021-05-08
2021
Engelska.
Ingår i: European Heart Journal. - : Oxford University Press. - 0195-668X .- 1522-9645. ; 42:31, s. 2995-3007
Relaterad länk:
https://doi.org/10.1...
visa fler...
https://uu.diva-port... (primary) (Raw object)
https://academic.oup...
https://urn.kb.se/re...
https://doi.org/10.1...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) events by 24% in 12 705 participants at intermediate CV risk after 5.6 years. There was no benefit of blood pressure (BP) lowering treatment in the overall group, but a reduction in events in the third of participants with elevated systolic BP. After cessation of all the trial medications, we examined whether the benefits observed during the active treatment phase were sustained, enhanced, or attenuated.Methods and results: After the randomized treatment period (5.6 years), participants were invited to participate in 3.1 further years of observation (total 8.7 years). The first co-primary outcome for the entire length of follow-up was the composite of myocardial infarction, stroke, or CV death [major adverse cardiovascular event (MACE)-1], and the second was MACE-1 plus resuscitated cardiac arrest, heart failure, or coronary revascularization (MACE-2). In total, 9326 (78%) of 11 994 surviving Heart Outcomes Prevention Evaluation (HOPE)-3 subjects consented to participate in extended follow-up. During 3.1 years of post-trial observation (total follow-up of 8.7 years), participants originally randomized to rosuvastatin compared with placebo had a 20% additional reduction in MACE-1 [95% confidence interval (CI), 0.64-0.99] and a 17% additional reduction in MACE-2 (95% CI 0.68-1.01). Therefore, over the 8.7 years of follow-up, there was a 21% reduction in MACE-1 (95% CI 0.69-0.90, P = 0.005) and 21% reduction in MACE-2 (95% CI 0.69-0.89, P = 0.002). There was no benefit of BP lowering in the overall study either during the active or post-trial observation period, however, a 24% reduction in MACE-1 was observed over 8.Conclusion: The CV benefits of rosuvastatin, and BP lowering in those with elevated systolic BP, compared with placebo continue to accrue for at least 3 years after cessation of randomized treatment in individuals without cardiovascular disease indicating a legacy effect. [GRAPHICS] .

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

Primary prevention
Cardiovascular disease
Statins

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy